Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs

Author(s): Elisabetta Gabano, Mauro Ravera, Donato Colangelo, Domenico Osella

Journal Name: Current Chemical Biology

Volume 1 , Issue 3 , 2007

Become EABM
Become Reviewer
Call for Editor


The history of inorganic pharmacology can be traced to antiquity with the medicinal use of inorganic salts, coordination and organometallic compounds. The clinical applications of metal-based drugs today are limited, but extremely significant. The most common metallo-therapeutic drugs are platinum, gold and bismuth compounds used in anticancer protocols and in the treatment of rheumatoid arthritis and gastric and duodenal ulcers, respectively. Platinum(II)-derivatives are the most widely prescribed anticancer agents, especially for polychemotherapy. Years of clinical experience have yielded detailed information about the quantitative structure-activity relationship (QSAR), pharmacokinetics and mechanisms of action of Pt-drugs. The accuracy of this information depends on precise measurement of Pt levels in body fluids, tissues, cells and DNA. Inductively Coupled Plasma - Mass Spectrometry (ICP-MS) offers higher sensitivity and accuracy than conventional analytical techniques, making it possible to detect trace concentrations of Pt-drugs at truly pharmacological concentrations. Increased knowledge about the action and fate of Pt-drugs may lead to important insights for the development of new metallo-pharmaceuticals with even wider applications.

Keywords: Antiproliferative agents, platinum complexes, cytotoxicity, pharmacokinetics, ICP-MS determination

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [278 - 289]
Pages: 12
DOI: 10.2174/2212796810701030278
Price: $25

Article Metrics

PDF: 7